ASH 2021

MRD: The new standard

clonoSEQ is the only FDA-cleared assay for assessing MRD in lymphoid malignancies. clonoSEQ has broad adoption and a growing body of evidence:

  • Featured in >30 abstracts at the ASH Congress
  • Performed on >18,500 unique patients to date
  • Clinically used in 30 of 31 NCCN® Member Institutions

For information on ordering clonoSEQ, call us at (888) 552-8988.



Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, MD, PhD, et al.



Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, MD, et al.



Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Jacob P. Laubach, et al.



Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Nina Shah, MD, et al.



Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Larry D. Anderson Jr., MD, PhD, et al.



A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Ben A. Derman, MD



Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yael C. Cohen, et al.



Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma

Jiasheng Wang, MD, et al.



CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Niels W.C.J. Van de Donk, et al.



Retrospective Analysis of Minimal Residual Disease Testing By High Throughput Immunosequencing Versus High Sensitivity Flow Cytometry in Multiple Myeloma

Anwar Khan, et al.


Product theater

The time is now: evidence for actionability of clonoSEQ MRD assessment in lymphoid cancer patient care.

Allison Jacob, MS
Medical Director, clonoSEQ

Sunday, December 12
11:30 am – 12:30 pm EDT

Tune into a live presentation with Allison Jacob from Adaptive Biotechnologies as she discusses the latest advances in next-generation sequencing for minimal residual disease (MRD) detection in lymphoid cancers including CLL, myeloma, and ALL.

Receive Event Notifications

Not an official event of the 63rd ASH Annual Meeting & Exposition. Not sponsored or endorsed by ASH. Not CME-accredited.

Presented by Adaptive Biotechnologies

Best of ASH: MRD Edition

In January 2022, Adaptive will sponsor a live webinar event to summarize the abundance of MRD data in lymphoid malignancies presented at ASH 2021.

Hear from experts in their respective fields on the established role of MRD as a clinical trial endpoint and the increasing relevance in clinical decision-making.

Receive Event Notifications

Corporate Reception

Join us to discuss how MRD is ready for prime time

Ventanas, Atlanta
Saturday, December 11, 2021
8:00-11:00 pm EDT

Join the Adaptive Biotechnologies team for an evening of conversation and engage with colleagues and experts alike to learn how MRD testing by clonoSEQ has been incorporated in their practices, all while enjoying panoramic views of the Atlanta skyline.

Discover clinicians’ real-world experience with clonoSEQ MRD testing

View cases, videos, patient perspectives and more, which illustrate how MRD testing by clonoSEQ may inform clinical decision-making.

Real-World Experience Data

clonoSEQ Product Resources

Learn more about clonoSEQ Assay by downloading these helpful resources:

  • clonoSEQ key publications
  • Talking to your patients about clonoSEQ results
  • clonoSEQ one-page overview
  • clonoSEQ insurance coverage summary
  • Clinical data summary: CLL MM ALL
  • Adaptive Assist patient support program overview
  • clonoSEQ reports walkthrough

Connect with Medical Affairs

Request information from a member of our Medical Affairs team.

Adaptive Immune Medicine Platform

Learn how the platform applies our proprietary technologies, computational biology, software and machine learning to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.

Twitter feed Follow us

This page is intended for a US-based audience.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). CLL Clonality (ID) Tests will also produce an IGHV status result, which is provided as a CLIA-validated laboratory developed test (LDT) but which has not been cleared or approved by the FDA. Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.